EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression

Qianqian Ma, Leilin Shao, Guangjun Jing, Fangyu Liu, Kaicheng Zhou, Fujie Wen, Haidong He, Dianwen Ju iD, Hong Xu iD

Antibody Therapeutics · 29.06.2026 · 9 (3) · 420-436

DOI: 10.1093/abt/tbag031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 16.06.2026. Verfasst von Qianqian Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal Intensive Care Uite, Shandong Medical and Pharmaceutical University Hospital, Binzhou 256600, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Collaborative Research Projects of Greater Bay Area Institute of Precision Medicine, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgroud Nephrotic syndrome (NS) is a major cause of end-stage renal disease. Treating NS relies on immunosuppressants, which have numerous side effects. Therefore, there is an urgent need to identify effective and safe alternative treatments for NS. Angiopoietin-like protein 3 (ANGPTL3) exacerbates proteinuria, whereas interleukin (IL)-22 has a reparative effect on renal cells.

Methods

In the present study, we developed a bifunctional anti-ANGPTL3/IL-22 fusion protein and validated its efficacy in an adriamycin-induced nephropathy in mice.

Results

The fusion protein significantly decreased the urinary albumin-to-creatinine ratio, serum creatinine, blood urea nitrogen, and total cholesterol levels while increasing serum albumin levels. Pathological renal damage was also alleviated. These therapeutic effects were accompanied by the preservation of mitochondrial integrity, reduced apoptosis, and inhibited autophagy. Finally, we humanized the fusion protein to facilitate its potential clinical translation.

Conclusions

In conclusion, our results revealed that the anti-ANGPTL3/IL-22 bifunctional fusion protein ameliorates NS by protecting mitochondria, inhibiting apoptosis, and suppressing autophagy, highlighting a novel therapeutic approach for NS.

Schlagwörter

Stichwörter der Autor:innen

angiopoietin-like protein 3apoptosisautophagybifunctional fusion proteininterleukin-22mitochondrianephrotic syndrome

Autor:innen und Institutionen

  • Neonatal Intensive Care Uite, Shandong Medical and Pharmaceutical University Hospital, Binzhou 256600, China.
  • Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.
  • iCareab Biotechnology Co. Ltd, Suzhou 215000, China.
  • Department of Neurology, Shandong Medical and Pharmaceutical University Hospital, Binzhou 256600, China.
  • Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
  • First People's Hospital of Kashi No. 120, Xinjiang 844000, China.

ORCID-Profile: Dianwen Ju, Hong Xu

Förderung

  • The Collaborative Research Projects of Greater Bay Area Institute of Precision Medicine
  • National Natural Science Foundation of China

Zitieren

APA

Ma, Q., Shao, L., Jing, G., Liu, F., Zhou, K., Wen, F., He, H., Ju, D., & Xu, H. (2026). Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression. Antibody Therapeutics, 9(3), 420-436. https://doi.org/10.1093/abt/tbag031

Vancouver

Ma Q, Shao L, Jing G, Liu F, Zhou K, Wen F, et al. Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression. Antibody Therapeutics. 2026;9(3):420-436. doi:10.1093/abt/tbag031

BibTeX
@article{Ma2026,
  author = {Ma, Qianqian and Shao, Leilin and Jing, Guangjun and Liu, Fangyu and Zhou, Kaicheng and Wen, Fujie and He, Haidong and Ju, Dianwen and Xu, Hong},
  title = {Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {420--436},
  doi = {10.1093/abt/tbag031}
}
Kostenlos starten →